Nkarta, Inc.

Mira Tohmé

Alexandra Leida Liana Lazetic

Chao Guo

James Barnaby Trager

Luxuan Guo Buren

Ivan Ho Chan

Ivan Chan

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.

Cancer immunotherapy using CD19-directed chimeric antigen receptors

Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Growing community of inventors

San Francisco, CA, United States of America

Mira Tohmé